Show simple item record

dc.contributor.authorPin Vieito, Noel
dc.contributor.authorIglesias, María J
dc.contributor.authorRemedios, David
dc.contributor.authorRodríguez Alonso, Lorena
dc.contributor.authorRodriguez Moranta, Francisco
dc.contributor.authorÁlvarez Sánchez, Victoria
dc.contributor.authorFernández Bañares, Fernando
dc.contributor.authorBoadas, Jaume
dc.contributor.authorMartínez Bauer, Eva
dc.contributor.authorCampo, Rafael
dc.contributor.authorBujanda Fernández de Pierola, Luis ORCID
dc.contributor.authorFerrández, Ángel
dc.contributor.authorPiñol, Virginia
dc.contributor.authorRodríguez Alcalde, Daniel
dc.contributor.authorGuardiola, Jordi
dc.contributor.authorCubiella, Joaquín
dc.contributor.authorCOLONPREDICT study investigators
dc.date.accessioned2020-06-12T08:35:17Z
dc.date.available2020-06-12T08:35:17Z
dc.date.issued2020-01-07
dc.identifier.citationWorld journal of gastroenterology 26 : 70-85 (2020)es_ES
dc.identifier.issn1007-9327
dc.identifier.issn2219-2840
dc.identifier.issn10.3748/wjg.v26.i1.70
dc.identifier.urihttp://hdl.handle.net/10810/43926
dc.description.abstractBACKGROUND Faecal immunochemical test (FIT) has been recommended to assess symptomatic patients for colorectal cancer (CRC) detection. Nevertheless, some conditions could theoretically favour blood originating in proximal areas of the gastrointestinal tract passing through the colon unmetabolized. A positive FIT result could be related to other gastrointestinal cancers (GIC). AIM To assess the risk of GIC detection and related death in FIT-positive symptomatic patients (threshold 10 mu g Hb/g faeces) without CRC. METHODS Post hoc cohort analysis performed within two prospective diagnostic test studies evaluating the diagnostic accuracy of different FIT analytical systems for CRC and significant colonic lesion detection. Ambulatory patients with gastrointestinal symptoms referred consecutively for colonoscopy from primary and secondary healthcare, underwent a quantitative FIT before undergoing a complete colonoscopy. Patients without CRC were divided into two groups (positive and negative FIT) using the threshold of 10 mu g Hb/g of faeces and data from follow-up were retrieved from electronic medical records of the public hospitals involved in the research. We determined the cumulative risk of GIC, CRC and upper GIC. Hazard rate (HR) was calculated adjusted by age, sex and presence of significant colonic lesion. RESULTS We included 2709 patients without CRC and a complete baseline colonoscopy, 730 (26.9%) with FIT >= 10 mu gr Hb/gr. During a mean time of 45.5 +/- 20.0 mo, a GIC was detected in 57 (2.1%) patients: An upper GIC in 35 (1.3%) and a CRC in 14 (0.5%). Thirty-six patients (1.3%) died due to GIC: 22 (0.8%) due to an upper GIC and 9 (0.3%) due to CRC. FIT-positive subjects showed a higher CRC risk (HR 3.8, 95%CI: 1.2-11.9) with no differences in GIC (HR 1.5, 95%CI: 0.8-2.7) or upper GIC risk (HR 1.0, 95%CI: 0.5-2.2). Patients with a positive FIT had only an increased risk of CRC-related death (HR 10.8, 95%CI: 2.1-57.1) and GIC-related death (HR 2.2, 95%CI: 1.1-4.3), with no differences in upper GIC-related death (HR 1.4, 95%CI: 0.6-3.3). An upper GIC was detected in 22 (0.8%) patients during the first year. Two variables were independently associated: anaemia (OR 5.6, 95%CI: 2.2-13.9) and age >= 70 years (OR 2.7, 95%CI: 1.1-7.0). CONCLUSION Symptomatic patients without CRC have a moderate risk increase in upper GIC, regardless of the FIT result. Patients with a positive FIT have an increased risk of post-colonoscopy CRC.es_ES
dc.description.sponsorshipSupported by Instituto de Salud Carlos III through the project PI17/00837 (Co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future").es_ES
dc.language.isoenges_ES
dc.publisherBaishideng Publishinges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectcolonoscopyes_ES
dc.subjectcolorectal canceres_ES
dc.subjectfaecal immunochemical testes_ES
dc.subjectgastric canceres_ES
dc.subjectgastroesophageal canceres_ES
dc.subjectgastrointestinal canceres_ES
dc.subjectoccult blood-testes_ES
dc.subjectcolorectal-canceres_ES
dc.subjectnegative colonoscopyes_ES
dc.subjectpopulationes_ES
dc.titleRisk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: role of faecal immunochemical testes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.wjgnet.com/1007-9327/full/v26/i1/70.htmes_ES
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/